Cover Image
市場調查報告書

原發性免疫不全症 (PID) : 開發平台分析

Primary Immune Deficiency (PID) - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 229789
出版日期 內容資訊 英文 72 Pages
訂單完成後即時交付
價格
Back to Top
原發性免疫不全症 (PID) : 開發平台分析 Primary Immune Deficiency (PID) - Pipeline Review, H2 2015
出版日期: 2015年11月30日 內容資訊: 英文 72 Pages
簡介

原發性免疫不全是免疫系統衰弱而不斷引起感染症。同時也容易造成其他健康障礙。症狀有血液感染、肺炎、支氣管炎、鼻竇感染、耳部感染、腦膜炎、皮膚感染疾病、痙攣、食慾不振、噁心和腹瀉等的消化器官障礙。

本報告提供原發性免疫不全症 (PID的)治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊,再加上最新的新聞和發表等資訊。

簡介

  • 調查範圍

原發性免疫不全症 (PID) 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • ADMA Biologics, Inc.
  • Baxter International Inc.
  • Genethon
  • GlaxoSmithKline plc
  • Green Cross Corporation
  • ProMetic Life Sciences Inc.
  • Sangamo BioSciences, Inc.
  • Sanofi

治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (immune globulin (human) + hyaluronidase (recombinant))
  • GC-1112
  • Gene Therapy for Severe Combined Immune Deficiency
  • Gene Therapy for X-Linked SCID
  • Gene Therapy to Activate Artemis for Radiosensitive Severe Combined Immunodeficiency
  • GSK-2696273
  • immune globulin (human)
  • immune globulin (human)
  • OT-81
  • plerixafor
  • RI-002
  • Stem Cell Therapy to Activate Adenosine Deaminase for Severe Combined Immune Deficiency
  • Stem Cell Therapy to Activate Adenosine Deaminase for Severe Combined Immune Deficiency
  • Stem Cell Therapy to Activate IL-2 Gamma Receptor for SCID-X1

最近的開發平台趨勢

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7349IDB

Summary

Global Markets Direct's, 'Primary Immune Deficiency (PID) - Pipeline Review, H2 2015', provides an overview of the Primary Immune Deficiency (PID)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Primary Immune Deficiency (PID), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Primary Immune Deficiency (PID) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Primary Immune Deficiency (PID)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Primary Immune Deficiency (PID) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Primary Immune Deficiency (PID) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Primary Immune Deficiency (PID) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Primary Immune Deficiency (PID)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Primary Immune Deficiency (PID) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Primary Immune Deficiency (PID) Overview
  • Therapeutics Development
    • Pipeline Products for Primary Immune Deficiency (PID) - Overview
    • Pipeline Products for Primary Immune Deficiency (PID) - Comparative Analysis
  • Primary Immune Deficiency (PID) - Therapeutics under Development by Companies
  • Primary Immune Deficiency (PID) - Therapeutics under Investigation by Universities/Institutes
  • Primary Immune Deficiency (PID) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Primary Immune Deficiency (PID) - Products under Development by Companies
  • Primary Immune Deficiency (PID) - Products under Investigation by Universities/Institutes
  • Primary Immune Deficiency (PID) - Companies Involved in Therapeutics Development
    • ADMA Biologics, Inc.
    • Baxalta Incorporated
    • Bellicum Pharmaceuticals, Inc.
    • Genethon
    • GlaxoSmithKline Plc
    • Green Cross Corporation
    • Octapharma AG
    • ProMetic Life Sciences Inc.
    • Sangamo BioSciences, Inc.
    • Sanofi
  • Primary Immune Deficiency (PID) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (immune globulin (human) + hyaluronidase (recombinant)) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BPX-501 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy for Severe Combined Immune Deficiency - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy for X-Linked SCID - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GSK-2696273 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NewNorm - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OT-81 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • plerixafor - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RI-002 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy to Activate Adenosine Deaminase for Severe Combined Immune Deficiency - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy to Activate Adenosine Deaminase for Severe Combined Immune Deficiency - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy to Activate Artemis for Radiosensitive Severe Combined Immunodeficiency - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy to Activate IL-2 Gamma Receptor for SCID-X1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Primary Immune Deficiency (PID) - Recent Pipeline Updates
  • Primary Immune Deficiency (PID) - Dormant Projects
  • Primary Immune Deficiency (PID) - Product Development Milestones
    • Featured News & Press Releases
      • Nov 03, 2015: ADMA Biologics Announces Data to be Presented at the International Primary Immunodeficiencies Congress in Budapest, Hungary
      • Oct 26, 2015: Prometic's IVIG IND Cleared By FDA
      • Sep 30, 2015: ADMA Biologics Receives Milestone Payment From Biotest for RI-002 BLA Submission to FDA
      • Sep 21, 2015: FDA Accepts ADMA Biologics License Application for RI-002
      • Aug 31, 2015: ADMA Biologics Receives Patent Issuance Pertaining to the Treatment of Immunodeficiency
      • Aug 03, 2015: Baxalta Announces Expanded CMS Coverage for Medicare PI Patients to Receive At-Home Treatment with HYQVIA
      • Jun 30, 2015: ADMA Biologics Receives Notice of Allowance for U.S. Patent Pertaining to Its Lead Product Candidate RI-002
      • Apr 27, 2015: GlaxoSmithKline Close To File For Marketing Approval For ADA-SCID Therapy In EU
      • Feb 23, 2015: ADMA Biologics Announces Positive Data on Primary and Secondary Endpoints from its Pivotal Phase III Clinical Trial for RI-002 at the AAAAI Medical Conference
      • Feb 17, 2015: ADMA Biologics Announces Data to be Presented at 2015 American Academy of Allergy Asthma & Immunology Annual Meeting (AAAAI)
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Primary Immune Deficiency (PID), H2 2015
  • Number of Products under Development for Primary Immune Deficiency (PID) - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Primary Immune Deficiency (PID) - Pipeline by ADMA Biologics, Inc., H2 2015
  • Primary Immune Deficiency (PID) - Pipeline by Baxalta Incorporated, H2 2015
  • Primary Immune Deficiency (PID) - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2015
  • Primary Immune Deficiency (PID) - Pipeline by Genethon, H2 2015
  • Primary Immune Deficiency (PID) - Pipeline by GlaxoSmithKline Plc, H2 2015
  • Primary Immune Deficiency (PID) - Pipeline by Green Cross Corporation, H2 2015
  • Primary Immune Deficiency (PID) - Pipeline by Octapharma AG, H2 2015
  • Primary Immune Deficiency (PID) - Pipeline by ProMetic Life Sciences Inc., H2 2015
  • Primary Immune Deficiency (PID) - Pipeline by Sangamo BioSciences, Inc., H2 2015
  • Primary Immune Deficiency (PID) - Pipeline by Sanofi, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Primary Immune Deficiency (PID) Therapeutics - Recent Pipeline Updates, H2 2015
  • Primary Immune Deficiency (PID) - Dormant Projects, H2 2015

List of Figures

  • Number of Products under Development for Primary Immune Deficiency (PID), H2 2015
  • Number of Products under Development for Primary Immune Deficiency (PID) - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Targets, H2 2015
  • Number of Products by Stage and Targets, H2 2015
  • Number of Products by Mechanism of Actions, H2 2015
  • Number of Products by Stage and Mechanism of Actions, H2 2015
  • Number of Products by Routes of Administration, H2 2015
  • Number of Products by Stage and Routes of Administration, H2 2015
  • Number of Products by Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top